Get the Stockscreener App
9.15
52.50%
3.15
After Hours:
9.10
-0.05
-0.55%
Optinose Inc stock is traded at $9.15, with a volume of 2.17M.
It is up +52.50% in the last 24 hours and up +52.50% over the past month.
OptiNose Inc is a specialty pharmaceutical company focuses on the development and commercialization of products for patients treated by ear, nose, and throat (ENT), and allergy specialists. Its first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing the proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.
See More
Previous Close:
$6.00
Open:
$9.5
24h Volume:
2.17M
Relative Volume:
32.95
Market Cap:
$60.33M
Revenue:
$75.67M
Net Income/Loss:
$-31.15M
P/E Ratio:
-32.95
EPS:
-0.2777
Net Cash Flow:
$-39.79M
1W Performance:
+70.39%
1M Performance:
+52.50%
6M Performance:
-19.91%
1Y Performance:
-64.43%
1-Day Range:
$9.09
$9.60
1-Week Range:
$5.33
$9.60
52-Week Range:
$4.815
$25.80
Optinose Inc Stock (OPTN) Company Profile
Name
Optinose Inc
Sector
Phone
267-364-3500
Address
777 TOWNSHIP LINE ROAD, YARDLEY, PA
Compare OPTN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OPTN
Optinose Inc
|
9.15 | 60.33M | 75.67M | -31.15M | -39.79M | -0.2777 |
|
ZTS
Zoetis Inc
|
163.16 | 73.33B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.16 | 47.80B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.39 | 46.89B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.24 | 18.61B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
131.60 | 13.99B | 612.78M | -86.37M | -62.91M | -0.87 |
Optinose Inc Stock (OPTN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-03-25 | Reiterated | H.C. Wainwright | Buy |
| Mar-11-24 | Initiated | H.C. Wainwright | Buy |
| Aug-21-23 | Initiated | Lake Street | Buy |
| Oct-21-22 | Resumed | Jefferies | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Dec-18-19 | Initiated | Cowen | Outperform |
| Aug-08-18 | Initiated | Cantor Fitzgerald | Overweight |
View All
Optinose Inc Stock (OPTN) Latest News
Paratek To Acquire Optinose, Expanding Portfolio Beyond Antibiotics - Scrip
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of OptiNose, Inc.OPTN - PR Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PRA, BECN, OPTN on Behalf of Shareholders - The Malaysian Reserve
Sector Update: Health Care Stocks Mixed in Afternoon Trading -March 20, 2025 at 02:03 pm EDT - Marketscreener.com
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Piper Sandler Downgrades OptiNose to Neutral From Overweight, $9 Price Target -March 20, 2025 at 12:32 pm EDT - Marketscreener.com
Optinose Shares Soar After Merger Agreement With Paratek Pharmaceuticals: Retail Sentiment Takes Flight - Asianet Newsable
Paratek to buy Optinose for up to $330 million - The Pharma Letter
Lake Street cuts Optinose stock rating, lowers target to $9 - Investing.com
Hold Rating Issued Amid Optinose Acquisition by Paratek Pharmaceuticals with Adjusted Price Target - TipRanks
OPTN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Optinose, Inc. Is Fair to Shareholders - Eagle-Tribune
OptiNose Stock Is Soaring Today: What's Going On? - Benzinga
Shareholder Alert: The Ademi Firm investigates whether Optinose, Inc. is obtaining a Fair Price for its Public Shareholders - Business Wire
OptiNose stock climbs on M&A deal with Paratek (OPTN:NASDAQ) - Seeking Alpha
OptiNose Surges Premarket Following Acquisition Agreement With Paratek Pharmaceuticals for Up to $330 Million - Marketscreener.com
Why Five Below Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket - Benzinga
Optinose Shares Surge Premarket on Takeover Deal With Paratek - MarketWatch
Optinose Stock: Paratek Acquires Firm for $330M - Sharewise
Paratek to acquire Optinose for up to $330 million By Investing.com - Investing.com South Africa
Paratek Pharmaceuticals to Acquire Optinose - citybiz
Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call - GlobeNewswire
Paratek Acquisition Prompts Optinose to Skip Q4 Earnings CallWhat's Next for Investors - StockTitan
Optinose Cancels Earnings Conference Call Following Acquisition Agreement with Paratek Pharmaceuticals - Nasdaq
Optinose CEO Mahmoud Ramy A sells $2,064 in common stock By Investing.com - Investing.com South Africa
Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call - GlobeNewswire Inc.
Paratek Pharmaceuticals To Acquire Optinose for Up To $330 Million -March 19, 2025 at 09:29 pm EDT - Marketscreener.com
Paratek Pharmaceuticals to Acquire Optinose, Creating Significant Commercial Expansion Opportunities for XHANCE® in Chronic Rhinosinusitis (CRS) - The Manila Times
Paratek to acquire Optinose for up to $330 million - Investing.com India
Optinose chief legal officer sells shares worth $1,380 By Investing.com - Investing.com South Africa
Optinose chief legal officer sells shares worth $1,380 - Investing.com India
Optinose CEO Mahmoud Ramy A sells $2,064 in common stock - Investing.com
(OPTN) Trading Advice - Stock Traders Daily
Optinose to Announce Q4 and Full-Year 2024 Financial Results on March 20, 2025 - MyChesCo
OptiNose (NASDAQ:OPTN) shareholders have endured a 90% loss from investing in the stock five years ago - Yahoo Finance
OptiNose (OPTN) Projected to Post Quarterly Earnings on Thursday - Defense World
Optinose Announces Reporting Date for Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire
Optinose to Announce Fourth Quarter and Full Year 2024 Financial Results on March 20, 2025 - Nasdaq
Optinose to Reveal Full Year Performance: Key Financial Results Coming March 20 - StockTitan
OptiNose, Inc. to Host Earnings Call - ACCESS Newswire
How the (OPTN) price action is used to our Advantage - Stock Traders Daily
Optinose CEO Mahmoud Ramy sells $33,729 in common stock By Investing.com - Investing.com South Africa
Optinose chief commercial officer sells $6,469 in stock - Investing.com India
Optinose chief commercial officer sells $6,469 in stock By Investing.com - Investing.com South Africa
Optinose CEO Mahmoud Ramy sells $33,729 in common stock - Investing.com
OptiNose Executives Sell Shares to Cover Tax Obligations - TradingView
Long Term Trading Analysis for (OPTN) - news.stocktradersdaily.com
OptiNose, Inc. (NASDAQ:OPTN) Sees Significant Growth in Short Interest - MarketBeat
(OPTN) Technical Pivots with Risk Controls - Stock Traders Daily
OptiNose, Inc. (NASDAQ:OPTN) Sees Significant Decline in Short Interest - MarketBeat
BECN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Beacon Roofing Supply, Inc. Is Fair to Shareholders - Business Wire
Optinose Reports $22.4 Million in Preliminary Q4 Revenue for XHANCE - MSN
Optinose Inc Stock (OPTN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.31%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):